Last CNY19.64 CNY
Change Today 0.00 / 0.00%
Volume 0.0
002462 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 08/11/14 All times are local (Market data is delayed by at least 15 minutes).

cachet pharmaceutical co-a (002462) Snapshot

Open
CNY19.46
Previous Close
CNY19.64
Day High
CNY19.66
Day Low
CNY19.36
52 Week High
02/25/14 - CNY21.23
52 Week Low
08/22/13 - CNY12.55
Market Cap
4.7B
Average Volume 10 Days
526.6K
EPS TTM
CNY0.54
Shares Outstanding
240.0M
EX-Date
06/12/14
P/E TM
36.4x
Dividend
CNY0.15
Dividend Yield
0.76%
Current Stock Chart for CACHET PHARMACEUTICAL CO-A (002462)

Related News

No related news articles were found.

cachet pharmaceutical co-a (002462) Related Businessweek News

No Related Businessweek News Found

cachet pharmaceutical co-a (002462) Details

Cachet Pharmaceutical Co., Ltd. is engaged in the wholesale and retail sale of pharmaceutical products in China. It is involved in the supply of medicines to hospitals; wholesale of biological products, medical instruments, and traditional Chinese medicines; pharmaceutical logistics; and manufacture of medicines. The company owns 150 chain stores in Beijing that sell medicines, health care food, medical instruments, cosmetics, daily necessities, and traditional Chinese medicines. Cachet Pharmaceutical Co., Ltd. was founded in 1998 and is based in Beijing, China.

Founded in 1998

cachet pharmaceutical co-a (002462) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cachet pharmaceutical co-a (002462) Key Developments

Miraculins Inc. Executes Definitive Agreement for the Sale and Distribution of Scout DS® Diabetes Screening Devices into China with Catalyn Medical Technologies Limited and Cachet Pharmaceutical Co., Ltd

Miraculins Inc. announced that it has executed a definitive agreement for the sale and distribution of Scout DS® diabetes screening devices into China with Catalyn Medical Technologies Limited. Cachet Pharmaceutical Co., Ltd. has been co-appointed as the exclusive distributor of the Scout DS® devices in Mainland China by Miraculins and Catalyn. The Scout DS® device is the world's first non-invasive and highly-sensitive testing device designed to measure diabetes related biomarkers in the skin to help detect pre-diabetes and type 2 diabetes. It does not require a blood draw or fasting and generates a result in as lit le as 80 seconds. The Scout DS® device uses visible light to measure the optical signature of fluorescent biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Key terms of the agreement include: the term of the agreement is to extend for five years from the date of procurement of CFDA (Chinese Food and Drug Administration) regulatory clearance of the Scout DS® device, subject to minimum Scout DS® device sales orders being met; Miraculins to receive certain upfront and milestone payments; initial minimum guaranteed order for USD 15 million in Scout DS® devices for the first year of the term, confirmed on execution of the Agreement, and to be activated on procurement of CFDA regulatory clearance of the Scout DS® device; subsequent minimum orders for USD 15 million in Scout DS® devices for each of years two, three and four of the term, totaling USD 45 million; subsequent minimum order for USD 30 million in Scout DS® devices in year five of the term; Miraculins to be responsible for leading the CFDA regulatory clearance process and its related costs, with Cachet providing guidance and support as necessary and Miraculins to retain the right to establish programs for ongoing device servicing and maintenance once the Scout DS® devices are sold into the field.

Miraculins Inc. Finalizes Agreement Terms for Cachet Pharmaceutical Co., Ltd. to Distribute Scout DS® Diabetes Screening Test in China

Miraculins Inc. announced that the company has finalized the major terms of a definitive agreement, that would see the Scout DS Diabetes Screening Test distributed exclusively in China by Cachet Pharmaceutical Co., Ltd. These terms are substantially similar to those outlined in the company's term sheet announcement made January 31, 2014, and include the placement of an initial order for Scout DS devices valued at USD 15 million on the signing of the Agreement, to be activated upon Chinese Food and Drug Administration regulatory clearance. Coinciding with the anticipated timing of the signing of the Agreement, a delegation from Cachet's senior management team in Beijing is scheduled to arrive in Canada in mid-July and will be conducting next stage distribution planning sessions with Miraculins. The Chinese delegation will also be visiting the production facility in the U.S. where the Scout DS devices will be manufactured, during their trip. The key deal terms will be announced once the Agreement has been executed. The execution of the Agreement remains subject to all final corporate approvals of the parties. There is no assurance that the parties will enter into the final Agreement.

Miraculins Updates Market on Distributor Discussions for Scout Ds® Diabetes Screening Test in China

Miraculins Inc. announced that it continues to advance discussions towards finalizing an agreement that would see the Scout DS test distributed exclusively in China by Cachet Pharmaceutical Co., Ltd. The completion of the Agreement and execution of definitive documentation remain subject to all necessary contractual, regulatory and corporate approvals of both Miraculins and Cachet and the completion of satisfactory due diligence. There is no assurance that the parties will enter into the Agreement or execute the definitive documentation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002462:CH CNY19.64 CNY 0.00

002462 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002462.
View Industry Companies
 

Industry Analysis

002462

Industry Average

Valuation 002462 Industry Range
Price/Earnings 20.5x
Price/Sales 1.2x
Price/Book 3.9x
Price/Cash Flow 20.2x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CACHET PHARMACEUTICAL CO-A, please visit www.cachet.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.